Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,166.38
(
0.02%
)
US TECH 100
26,525.15
(
-0.11%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
102.03
(
0.49%
)
Bitcoin
76,679.58
(
-2.51%
)
News Focus
News Focus
Post# of 257448
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122891
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 228031

Wednesday, 01/08/2020 2:50:48 PM

Wednesday, January 08, 2020 2:50:48 PM

Post# of 257448
FDA approves Keytruda monotherapy for second-line NMIBC, regardless of PD-L1 status:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer

This accelerated approval is based on the single-arm KEYNOTE-057 study. ODAC backed approval by a 9-4 vote (#msg-152848797).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today